UNSPSC 51131831: Emicizumab

A hemophilia A treatment approved for people with hemophilia A with or without factor VIII inhibitors.

UNSPSC 51131831 Emicizumab is a Commodity code that names a monoclonal antibody used to treat hemophilia A. State and local procurement activity under this code shows little relevant recent urgency—the opportunities block contains no active solicitations for emicizumab itself, only tangentially related pharmaceutical and medical supply procurements that do not target this specific biopharmaceutical.

The source shows no recent state or local government solicitations requesting emicizumab directly. A June 2026 Seminole County, Florida ITQ for naloxone and drug deactivation systems, a June 2026 City of Tucson RFP for BLS/ALS pharmaceuticals and medical supplies, and a January 2026 Pinellas County ITQ for forensic drug standards represent the pharmaceutical procurement activity in the dataset, but none align with hemophilia A treatment or emicizumab use. A January 2026 MMCAP RFP for generic multi-source pharmaceuticals and OTC products through cooperative purchasing also does not target specialty biologics like emicizumab. The code appears dormant under current state and local procurement—this is a niche specialty pharmaceutical unlikely to generate high-volume government demand outside hospital formularies and state Medicaid programs, neither of which are signaling active solicitations at present.